Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Taro Pharmaceutical Industries's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Taro Pharmaceutical Industries could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Taro Pharmaceutical Industries's Cash-to-Debt or its related term are showing as below:

TARO' s Cash-to-Debt Range Over the Past 10 Years
Min: 35.39 Med: No Debt Max: No Debt
Current: 462.68

During the past 13 years, Taro Pharmaceutical Industries's highest Cash to Debt Ratio was No Debt. The lowest was 35.39. And the median was No Debt.

TARO's Cash-to-Debt is ranked better than
92.56% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs TARO: 462.68

Taro Pharmaceutical Industries Cash-to-Debt Historical Data

The historical data trend for Taro Pharmaceutical Industries's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Taro Pharmaceutical Industries Cash-to-Debt Chart

Taro Pharmaceutical Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

732.32

606.07

372.39

436.05

Taro Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	436.05	No Debt	No Debt	No Debt

Competitive Comparison of Taro Pharmaceutical Industries's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taro Pharmaceutical Industries's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Cash-to-Debt falls into.

Taro Pharmaceutical Industries Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Taro Pharmaceutical Industries's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	850.289	/	(1.95	+	0)
	=	436.05

Taro Pharmaceutical Industries's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Taro Pharmaceutical Industries had no debt ⁽¹⁾.

Taro Pharmaceutical Industries (NYSE:TARO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Taro Pharmaceutical Industries Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

TAL:Germany

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Executives

Sun Pharma Global Inc	10 percent owner
Sun Pharmaceutical Industries Ltd	10 percent owner, other: Affiliated Party	17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd.	10 percent owner	KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc	10 percent owner	FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403